Chalkis Health Industry Co (000972) Fair Value & Analysis
Consumer Defensive · CN · Market cap 2.8B CNY
Fair value as of: Jun 25, 2026
Analysis
Chalkis Health Industry Co (000972) currently trades at ¥3.34, while our model-based Fair Value estimate is ¥2.71 — implying the stock looks roughly 18.9% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Chalkis Health Industry Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of tomatoes in China and internationally. The company offers tomato sauces, lycopene vitamin E soft capsules, tomato cubes, peeled whole tomatoes, and tomato and sea buckthorn compressed candies. It sells its products through online and offline channels. The company also engages in the planting of tomatoes; processing of agricultural products; technological development; tender brokerage; investment management; research and trial development; wholesale trade; agriculture; retail; and science and technology promotion and application activities. The company was formerly known as Xinjiang Chalkis Co., Ltd. and changed its name to Chalkis Health Industry Co., Ltd. in May 2016. Chalkis Health Industry Co., Ltd. was founded in 1994 and is headquartered in Wujiaqu, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Chalkis Health Industry Co (000972) undervalued?
What is the fair value of 000972?
What is the quality score of 000972?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.